公开(公告)号：EP2037936B1

公开(公告)日：2014-06-11

申请号：EP07840277.3

申请日：2007-06-21

申请人： Proventiv Therapeutics, LLC ,  Cytochroma Inc.

发明人： BISHOP, Charles, W. ,  CRAWFORD, Keith, H. ,  MESSNER, Eric, J. ,  PETKOVICH, P. Martin ,  HELVIG, Christian, F.

IPC分类号： A61K31/59 ,  A61P5/20

CPC分类号： A61K31/593 ,  A61K9/48 ,  A61K31/59 ,  A61K31/592

摘要： A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.